EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Recombinant Human Thrombopoietin Combined With Avatrombopag for Chemoradiotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma: A Prospective, Randomized Controlled Trial

Ting Jin, Qifeng Jin, Yonghong Hua, Shuang Huang, Xiaozhong Chen

British Journal of Hospital Medicine · 2025

DOI: 10.12968/hmed.2025.0641 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Hospital Medicine, 2025. Verfasst von Ting Jin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, Ch…. Hauptthemen laut MEDLINE: Chemoradiotherapy, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Thiazoles. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/Background Chemoradiotherapy-induced thrombocytopenia is a frequent dose-limiting toxicity in nasopharyngeal carcinoma (NPC). Thrombopoietin receptor agonists have shown potential in accelerating platelet recovery. This study aimed to evaluate the clinical efficacy of recombinant human thrombopoietin (rhTPO) combined with avatrombopag in treating chemoradiotherapy-induced thrombocytopenia in NPC patients.

Methods

A total of 42 NPC patients receiving chemoradiotherapy at Zhejiang Cancer Hospital between May 2023 and June 2024 were randomly allocated into an experimental group (n = 21) and a control group (n = 21) using the envelope method. The control group received avatrombopag alone, whereas the experimental group was administered rhTPO plus avatrombopag. Clinical efficacy, platelet parameters, serological indicators, and adverse events were assessed and compared.

Results

No significant difference was observed between groups in the overall response rate (95.24% vs. 71.43%) (χ 2 = 2.743, p = 0.098). Before treatment, platelet parameters and serological indicators did not differ significantly between groups (p > 0.05). Following treatment, platelet distribution width (PDW) and mean platelet volume (MPV) were significantly reduced, while plateletcrit (PCT) was significantly elevated in the experimental group compared to the control group (p < 0.05). Additionally, serum levels of thrombopoietin (TPO), signal transducer and activator of transcription 3 (STAT3), and mitogen-activated protein kinase (MAPK) were markedly elevated in the experimental group (p < 0.05). The incidence of adverse events did not differ significantly between groups (47.62% vs. 52.38%, χ 2 = 0.095, p = 0.758).

Conclusion

The combination of rhTPO and avatrombopag demonstrates potential clinical efficacy with a favorable safety profile. However, larger randomized controlled trials are warranted to validate these findings. Clinical Trial Registration Chinese Clinical Trial Registry ( ChiCTR2400081992 ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChemoradiotherapyNasopharyngeal CarcinomaNasopharyngeal NeoplasmsThiazolesThiophenesThrombocytopeniaThrombopoietinAdultAgedFemaleHumansMaleMiddle AgedDrug Therapy, CombinationProspective StudiesRecombinant ProteinsTreatment Outcome

Stichwörter der Autor:innen

avatrombopagchemoradiotherapyclinical efficacynasopharyngeal carcinomarecombinant human thrombopoietinthrombocytopenia

Substanzen

avatrombopagRecombinant ProteinsThiazolesThiophenesThrombopoietin

Autor:innen und Institutionen

  • Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.

Zitieren

APA

Jin, T., Jin, Q., Hua, Y., Huang, S., & Chen, X. (2025). Recombinant Human Thrombopoietin Combined With Avatrombopag for Chemoradiotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma: A Prospective, Randomized Controlled Trial. British Journal of Hospital Medicine. https://doi.org/10.12968/hmed.2025.0641

Vancouver

Jin T, Jin Q, Hua Y, Huang S, Chen X. Recombinant Human Thrombopoietin Combined With Avatrombopag for Chemoradiotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma: A Prospective, Randomized Controlled Trial. British Journal of Hospital Medicine. 2025. doi:10.12968/hmed.2025.0641

BibTeX
@article{Jin2025,
  author = {Jin, Ting and Jin, Qifeng and Hua, Yonghong and Huang, Shuang and Chen, Xiaozhong},
  title = {Recombinant Human Thrombopoietin Combined With Avatrombopag for Chemoradiotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma: A Prospective, Randomized Controlled Trial},
  journal = {British Journal of Hospital Medicine},
  year = {2025},
  doi = {10.12968/hmed.2025.0641}
}
Kostenlos starten →